1. Formula compound (1) and its pharmaceutical components referred to in this document regulate the activity of adrenaline B-3 recipients. Current compounds and their pharmaceutical components are useful methods for the treatment of moderate disorders of adrenaline B-3 receptor, such as heart failure； cardiac manifestations of heart failure； mortality, recurrence and / or hospitalization rates related to heart failure； Keywords acute heart disease； acute failure heart disease； congestive heart disease； severe congestive heart disease；Organ damage related to heart failure (such as kidney damage or failure, heart valve problems, heart rate problems and / or liver damage)；Keywords heart failure caused by left ventricular dysfunction； heart failure in normal ejaculation； cardiovascular death after myocardial infarction； cardiovascular death in patients with left ventricular failure or left ventricular failure； left ventricular failure； Left ventricular dysfunction； secondary heart failure, using the New York Heart Association classification system；3. A tertiary heart disease study using the NYHA classification system；4. Use the classification system of New York Heart Association (Nyca) for the fourth level of heart disease treatment；LVEF lt； 40% were radionuclide ventriculography； 35% were ventricular ultrasound or contrast angiography and related diseases. 1. Characteristic 1: a selected formula compound (1), its salts, solutions and drug acceptable hydrates, wherein X is - so8322a；-C (=O)o -CH C (3DO) -W is absent or C₁₋₃alkylene； R¹ is aryl or heteroaryl； where each is optionally substituted with one or more substituents selected from: C₁₋₆alkoxy, C₁₋₆alkyl, amino, cyano, C₃₋₇cycloalkyl, C₁₋₆haloalkyl, halogen, hydroxyl, oxo, and sulfamoyl； and wherein said C₁₋₆alkyl and C₃₋₇cycloalkyl are each optionally substituted with one or more substituents selected from: amino, C₁₋₆alkoxy, C₁₋₆alkylcarboxamide, -Y-C₃₋₇-cycloalkyl, -Y-C₁₋₆-alkylene -Z, C₁₋₆alkyloamino, C₁₋₆hal
